Anika Therapeutics announces departure of COO Anne Nunes, eliminates position

Anika Therapeutics, Inc.

Anne Nunes departs as Chief Operations Officer effective April 25, 2025.
She receives severance per her Executive Retention Agreement (filed as Exhibit 10.14 to 10-K).
Stephen Griffin (EVP, CFO, COO) assumes manufacturing and operations functions.
Company eliminates Chief Operations Officer role; no replacement planned.
Griffin's annual compensation remains unchanged.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Anne Nunes

Chief Operations Officer

ANIK · Anika Therapeutics, Inc.

Effective: 2025-04-25
Filed: April 10, 2025, 7:59 PM ET

On April 4, 2025, Anika Therapeutics, Inc. (the “Company”) announced the departure of Anne Nunes, Chief Operations Officer, effective April 25, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Anne Nunes departed as Chief Operations Officer at Anika Therapeutics, Inc..

Action: departed
Role: Chief Operations Officer

Exact text from the filing

On April 4, 2025, Anika Therapeutics, Inc. (the “Company”) announced the departure of Anne Nunes, Chief Operations Officer, effective April 25, 2025.

View on SEC.gov

Anika Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-25-002148

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.